The tyrosine kinase adaptor protein FRS2 is oncogenic and amplified in high-grade serous ovarian cancer

Molecular Cancer Research

Volumn 13, Issue 3, 2015, Pages 502-509

  Luo, Leo Y ^a,b,c   Kim, Eejung ^b,c   Cheung, Hiu Wing ^b,d   Weir, Barbara A ^b   Dunn, Gavin P ^b,e   Shen, Rhine R ^c,f   Hahn, William C ^b,c,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TYROSINE KINASE ADAPTOR PROTEIN FRS2; UNCLASSIFIED DRUG; FRS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CANCER SURVIVAL; CHROMOSOME 12Q; CONTROLLED STUDY; GENE AMPLIFICATION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; ONCOGENE; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 12; CYSTADENOCARCINOMA; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 12; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE AMPLIFICATION; HUMANS; MEMBRANE PROTEINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS;

EID: 84928009182     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0407     Document Type: Article

References (40)

1. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8.
2. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011;108:12372-7.
4. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang XP, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 2008;105:20380-5.
5. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
6. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
7. Liu JS, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
8. Lamesch P, Li N, Milstein S, Fan C, Hao T, Szabo G, et al. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics 2007;89:307-15.
9. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79.
10. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006;7:R100.
11. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4:2126.
12. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 2013;8:e72162.
13. Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 2013;110:19489-94.
14. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
15. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
16. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 2012;4:147ra12.
17. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011; 108:7547-52.
18. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010;29:1103-13.
19. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 2013;495:241-5.
20. Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 2014;111:1102-7.
21. Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A 2001;98:8578-83.
22. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A 2001;98:6074-9.
23. Zhang KQ, Chu KV, Wu XW, Gao HL, Wang JH, Yuan YC, et al. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in highgrade liposarcoma. Cancer Res 2013;74:1298-307.
24. Wang XK, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang HY, Moura RD, et al. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer 2011;50:849-58.
25. Cappellen D, De Oliveira C, Ricol D, de Medina SGD, Bourdin J, Sastre- Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
26. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, DiBacco A, et al. FGFR2- amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8.
27. Dutt A, Salvesen HB, Chent TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008;105:8713-7.
28. Weiss J, Sos L, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (vol 3, 66er5, 2011). Sci Transl Med 2010;2:62ra93.
29. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-Sensitive FGFR1 amplification in human non-small cell lung cancer. Plos ONE 2011;6:e20351.
30. Easton DF, Pooley KA, Dunning AM, Pharoah PDP, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-U7.
31. Sawey ET, Chanrion M, Cai CL, Wu GM, Zhang JP, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011;19: 347-58.
32. Harding TC, Long L, Palencia S, Zhang HB, Sadra A, Hestir K, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013;5:178ra39.
33. Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 2013;3:1044-57.
34. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, et al. The Sh2 and Sh3 domain containing protein Grb2 links receptor tyrosine kinases to ras signaling. Cell 1992;70:431-42.
35. Warner N, Nunez G. MyD88: a critical adaptor protein in innate immunity signal transduction. J Immunol 2013;190:3-4.
36. Kouhara H, Hadari YR, SpivakKroizman T, Schilling J, BarSagi D, Lax I, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997;89:693-702.
37. Cheung HW, Du JY, Boehm JS, He F, Weir BA, Wang XX, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011;1:608-25.
38. Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 2014; 111:1102-7.
39. Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, et al. Identification of druggable cancer driver genes amplified across TCGA datasets. Plos ONE 2014;9:e98293.
40. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.